NCT05952960已完成不适用
Optimizing Open Label Placebo Rationales for Chronic Pain
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Pain Reports
研究概览
简要总结
A 3-arm randomized trial where all chronic pain patients will receive honest placebos, but the information about the placebos will differ between conditions. Outcomes are measured for 21 days and a qualitative survey will be conducted.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •chronic pain
- •18 years old
- •English speaking
- •have a smartphone or computer with video access
- •Taking prescription opioids for chronic pain
- •the chronic pain is concentrated into the patient's lower back.
排除标准
- •suspect an allergy to any placebo ingredient
- •problematic substance use
- •cancer diagnosis causing pain
- •anticipated change in opioid script during the study period.
研究组 & 干预措施
TAU Rationale
Other
Rationale based on prior OLP studies (e.g. Kaptchuk et al., 2010)
干预措施: Placebo (Other)
Mindfulness Rationale
Other
Rationale based on mindfulness meditation
干预措施: Placebo (Other)
Suspension of Disbelief Rationale
Other
Rationale based on suspending disbelief about the placebo
干预措施: Placebo (Other)
结局指标
主要结局
Pain Reports
时间窗: 21 days
Brief Pain Inventory: Pain intensity and pain interference
次要结局
- Opioids(21 Days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Open Label Placebo to Reduce Prescription Opioid UseAcute PainNCT05014230Brown University155
已完成
不适用
Are pills enough? The influence of information on open-label placebo effects in healthy volunteersegative emotional statePositive mental wellbeingPhysical symptomsSleep qualityACTRN12617001092381Dr Kate Faasse90
招募中
不适用
Placebo Impacts Sleep and Pain Modulation in Chronic PainChronic PainHeadacheNCT06225817University of Maryland, Baltimore111
已完成
2 期
Open Label Placebo in the Treatment of Low Back PainChronic Low Back PainNCT02022124Hospital de Egas Moniz83
已完成
3 期
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeWHIM SyndromeNCT03995108X4 Pharmaceuticals31